Zalcitabine

CHEMBL853 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
211.2 g/mol
LogP
-1.3
Phase
4

Zalcitabine (ddC, 2',3'-dideoxycytidine) is a nucleoside reverse transcriptase inhibitor (NRTI) that, after phosphorylation to its active triphosphate form, competitively inhibits HIV-1 reverse transcriptase and terminates nascent viral DNA chain elongation. It was one of the early antiretroviral agents approved for HIV/AIDS treatment. It is no longer clinically used due to its significant toxicity profile, including peripheral neuropathy and pancreatitis, and has been superseded by better-tolerated NRTIs.

น้ำหนักโมเลกุล

211.2200 g/mol

LogP

-1.30

TPSA

88.20 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1

InChI

InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1

Molecular Formula

C9H13N3O3

HBD / HBA

2 / 3

พันธะที่หมุนได้

2

อะตอมหนัก

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Zalcitabine (ddC, 2',3'-dideoxycytidine) is a nucleoside reverse transcriptase inhibitor (NRTI) that, after phosphorylation to its active triphosphate form, competitively inhibits HIV-1 reverse transcriptase and terminates nascent viral DNA chain elongation. It was one of the early antiretroviral agents approved for HIV/AIDS treatment. It is no longer clinically used due to its significant toxicity profile, including peripheral neuropathy and pancreatitis, and has been superseded by better-tolerated NRTIs.

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Yes, Zalcitabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL853. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 24066. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.